2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
HR+HER2- Advanced Breast Cancer
1
Glioblastoma
1
Disease
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Gastric Cancer
1
Interventions
Cisplatin
13
Etoposide
11
Paclitaxel
8
Cyclophosphamide
7
Carboplatin
7
Ifosfamide
6
etoposide phosphate
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
pembrolizumab
4
fludarabine
4
Sirolimus
4
Bleomycin
4
fludarabine phosphate
3
Sunitinib
3
Oxaliplatin
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bevacizumab
3
Automobiles
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
sodium thiosulfate
2
ribociclib
2
pralsetinib
2
pegfilgrastim
2
lutetium Lu 177 dotatate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Drug Therapy, Combination
×
Clear all
NCT01782339
2024-06-14
GAMMA
Barts & The London NHS Trust
Phase 2
Completed
45 enrolled